{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -2.16, "sharesOutstanding": 3427320, "bookValue": 1.048, "fiftyDayAverage": 53.386, "fiftyDayAverageChange": 21.414001, "fiftyDayAverageChangePercent": 0.4011164, "twoHundredDayAverage": 43.5485, "twoHundredDayAverageChange": 31.251503, "twoHundredDayAverageChangePercent": 0.71762526, "marketCap": 263804656, "priceToBook": 71.374054, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "currency": "PLN", "financialCurrency": "PLN", "regularMarketOpen": 75.0, "averageDailyVolume3Month": 5651, "averageDailyVolume10Day": 5681, "fiftyTwoWeekLowChange": 46.100002, "fiftyTwoWeekLowChangePercent": 1.6062719, "fiftyTwoWeekRange": "28.7 - 80.0", "fiftyTwoWeekHighChange": -5.199997, "fiftyTwoWeekHighChangePercent": -0.06499996, "fiftyTwoWeekLow": 28.7, "fiftyTwoWeekHigh": 80.0, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "firstTradeDateMilliseconds": 1636358400000, "priceHint": 2, "marketState": "REGULAR", "regularMarketChange": -1.0, "regularMarketTime": 1684141115, "regularMarketDayHigh": 75.6, "regularMarketDayRange": "74.0 - 75.6", "regularMarketDayLow": 74.0, "regularMarketVolume": 1267, "regularMarketPreviousClose": 75.8, "bid": 74.4, "ask": 74.8, "fullExchangeName": "Warsaw", "regularMarketChangePercent": -1.3192612, "regularMarketPrice": 74.8, "exchangeTimezoneName": "Europe/Warsaw", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "WSE", "shortName": "BIOCELTIX", "longName": "Bioceltix S.A.", "messageBoardId": "finmb_599022432", "market": "pl_market", "symbol": "BCX.WA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Building III", "address2": "Bierutowska 57-59 Street", "city": "Wroclaw", "zip": "51-317", "country": "Poland", "phone": "48 71 880 8771", "fax": "48 71 734 5509", "website": "https://bioceltix.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Grzegorz  Ostropolski", "title": "Chief Exec. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Lukasz  Bzdzion", "title": "Pres of the Management Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Andrij  Wlach", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Pawel  Wielgus", "title": "Member of the Management Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Jakub  Grzesiak", "title": "Technology Director", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}